Fig. 2: Chemical optimization of PK6 leads to improvements in anti-necroptotic activity. | Cell Death & Disease

Fig. 2: Chemical optimization of PK6 leads to improvements in anti-necroptotic activity.

From: Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis

Fig. 2

a, b The effects of the indicated compounds on cell viability were examined in HT-29 cells (a) and L929 cells (b). HT-29 cells were treated as indicate for 48 h and L929 cells for 24 h. Cell viability was assessed by measuring ATP levels. Data are represented as the mean ± standard deviation of triplicates. c Structure and EC50 ± SD value of each compound are shown in the table. EC50 values are the average of at least two independent determinations. d Lead optimization of PK6

Back to article page